Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€6.97

€6.97

-3.460%
-0.25
-3.460%
-
 
15.07.24 / Tradegate WKN: A14QXP / Name: Ose Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Ose Pharma International S.A. Stock

Ose Pharma International S.A. took a tumble today and lost -€0.250 (-3.460%).
For the coming years our community has positive and negative things to say abot the Ose Pharma International S.A. stock. Criterium "EBIT growth" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.

Pros and Cons of Ose Pharma International S.A. in the next few years

Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Prediction Buy
Perf. (%) -21.54%
Target price 5.500
Change
Ends at 27.12.17

(Laufzeit überschritten)
Show more

Prediction Buy
Perf. (%) -21.54%
Target price 5.500
Change
Ends at 27.12.17

Fortsetzung der Erholung

Der Wert Tiefpunkte erreicht und sollte Rebound weiter

Show more

News

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update: https://mms.businesswire.com/media/20230215005587/en/545518/5/OSE_LOGO_Horizontal_RVB.jpg
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update


Regulatory News:



OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical

OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook: https://mms.businesswire.com/media/20230215005587/en/545518/5/OSE_LOGO_Horizontal_RVB.jpg
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook


Regulatory News:



OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) updates on its clinical portfolio advancements and provides 2024 outlook.



Nicolas Poirier, Chief Executive Officer